In this video series, Professor Nicolas van Mieghem will discuss the benefits of iVAC 2L in clinical practice and will share the learnings and key outcomes from the PULSE-Trial, and the effect of next generation pulsatile mechanical circulatory support (MCS). Also this video series has been broken down into 12 shorter clips. Please follow this link.
Partnership accelerates the development of the iVAC 2L mechanical circulatory device in Greater China. Expands Huadong Medicine’s medical portfolio for cases of high-risk PCI with innovative percutaneous ventricle assist devices based on innovative pulsatile technology. PulseCath will receive a significant investment in its share capital and in payments for regulatory and development activities and is eligible to royalties on iVAC’s commercial sales by Huadong Medicine in their commercial region. ARNHEM, THE NETHERLANDS and HANGZHOU, PRC, September 17, 2021 — PulseCath B.V., a leader in the expanding field of percutaneous ventricular assist devices for high-risk PCI, and Huadong Medicine Co., Ltd., today announced that the companies have entered into an exclusive collaboration to develop and commercialize the iVAC technology in mainland China, Hong Kong, Macau and Taiwan (Greater China) and selected other Asian Pacific countries. The collaboration agreement between PulseCath and Huadong provides Huadong Medicine with a license to distribute iVAC […]
An expert consensus has been released by the Joint European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Association for Acute Cardiovascular Care (ACVC) reviewing the pathophysiological context and indications for pVADs in different clinical settings. It also provides guidance regarding the clinical management of patients requiring pVADs. A quick overview is made on the state-of-the art of short-term mechanical circulatory support according to different indications. Additional discussions on the handling of complications, anticoagulation and weaning are also provided. The appendix section describes the theoretical basis for the use of different MCS devices, including how their effects differ. The review has been published on EuroIntervention. Please follow this link for the full publication.
Dr. Ota Hlinomaz, interventional cardiologist at CINRE hospital in Slovak Republic presented during the EuroPCR 2021: Improving outcomes of high-risk protected distal left main intervention by pulsatile circulatory support system. For more information please follow this link.
Please follow on demand the Live Case iVAC 2L at TIO 2021 performed by Prof. Nicolas van Mieghem, Erasmus Medical Center, Rotterdam, the Netherlands.
The recording of the CSI FOCUS D-HF: Mechanical circulatory support from is available on-demand. (after free registration). The presentation about PulseCath iVAC 2L by Prof. Dr. Nicolas van Mieghem, Erasmus Medical Center, Rotterdam, Netherlands starts at 01:40:42. The CSI Focus D-HF interactive webinar series will provide a comprehensive overview of device based therapy in heart failure, including advancements in ventricle restoration strategies, device based strategies to improve cardiac output, monitoring systems and other cutting edge technologies and emerging platforms in this new field.
Please follow these links to the webinars during ACS Live in Turkey 2020:
In November 2020 hosted by Prof. Dr. Nicolas M. Van Mieghem, MD, PhD, FACC, FESC Professor & Director of Interventional Cardiology Thoraxcenter, Erasmus University Medical Center Rotterdam, the Netherlands. Follow this link for the presentation
Five sessions in November 2020 hosted by Dr. Joost Daemen, MD, PHD, FESC. Interventional cardiologist, Thoraxcenter, Erasmus Medical Center, the Netherlands. Please follow the link for the online webinar.
Meet Us At TCT 2019, Sep’ 26-28 – Booth# 1757
